Press release
May 7, 2026
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
LeonaBio, Inc. (LONA)
Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Expects to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in Treatment-Resistant